Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 87 Results

Title
Intervention Indication Therapeutic Area Year Actions
Osimertinib for EGFR-positive non-small cell lung cancer - adjuvant Osimertinib (Tagrisso; AZD9291; osimertinib mesylate) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Osimertinib maintenance therapy for treating stage III unresectable EGFR mutation positive non-small-cell lung cancer after definitive platinum-based chemoradiation therapy Osimertinib (Tagrisso; AZD9291; osimertinib mesylate) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Pembrolizumab (Keytruda) for non‐small cell lung cancer - first line, previously untreated Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Pembrolizumab (KEYTRUDA) in combination with carboplatin-paclitaxel/Nab-paclitaxel for metastatic squamous non small cell lung cancer, first line Carboplatin (Paraplatin) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , Paclitaxel (Taxol; paclitaxel albumin) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Pembrolizumab and chemotherapy for resectable nonsmall-cell lung cancer Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Pembrolizumab in addition to lenvatinib for PD-L1 positive (at least 1%) non-small-cell lung cancer – first line Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Pembrolizumab in addition to platinumpemetrexed chemotherapy for metastatic EGRF mutant non-squamous non-small-cell lung cancer – second line Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Pembrolizumab in combination with ipilimumab for advanced non-small cell lung cancer Ipilimumab (Yervoy; BMS 734016; MDX 101) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Pembrolizumab in combination with lenvatinib, platinum chemotherapy, and pemetrexed for non-small cell lung cancer Chemotherapy , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
Pembrolizumab in combination with olaparib as maintenance therapy for non-small-cell lung cancer following first line treatment Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
1 2 4 5 6 7 8 9
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications